US2017183685A1PendingUtilityA1

Ungulates with Genetically Modified Immune Systems

61
Assignee: REVIVICOR INCPriority: Oct 22, 2004Filed: Feb 13, 2017Published: Jun 29, 2017
Est. expiryOct 22, 2024(expired)· nominal 20-yr term from priority
C12N 15/8509A01K 2227/103A01K 2207/15C12N 2800/206A01K 2267/025A01K 2217/075A01K 2267/02A01K 2267/0387A01K 2227/102A01K 67/0275C12N 2015/8536C12N 2800/204A01K 67/0276A01K 2227/101A01K 2227/108C12N 15/873C12N 2800/30A01K 2217/00A01K 2267/01
61
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides ungulate animals, tissue and organs as well as cells and cell lines derived from such animals, tissue and organs, which lack expression of functional endogenous immunoglobulin loci. The present invention also provides ungulate animals, tissue and organs as well as cells and cell lines derived from such animals, tissue and organs, which express xenogenous, such as human, immunoglobulin loci. The present invention further provides ungulate, such as porcine genomic DNA sequence of porcine heavy and light chain immunoglobulins. Such animals, tissues, organs and cells can be used in research and medical therapy. In addition, methods are provided to prepare such animals, organs, tissues, and cells.

Claims

exact text as granted — not AI-modified
1 . A targeting vector comprising: (a) a first nucleotide sequence comprising at least 17 contiguous nucleic acids homologous to SEQ ID No 28 or 31; (b) a selectable marker gene; and (c) a second nucleotide sequence comprising at least 17 contiguous nucleic acids homologous to SEQ ID No 28 or 31, which does not overlap with the first nucleotide sequence.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.